Research programme: stapled peptide therapeutics - Rein Therapeutics/Roche
Alternative Names: ATSP-7041; MDM2/MDMX dual inhibitor for p53-dependent cancers - Rein Therapeutics/RocheLatest Information Update: 21 Jan 2025
At a glance
- Originator Aileron Therapeutics; Roche
- Developer Rein Therapeutics; Roche
- Class Peptides
- Mechanism of Action Protein modulators; Proto-oncogene protein c-mdm2 inhibitors; Tumour suppressor protein p53 stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported CNS disorders; Haematological malignancies; Inflammation; Metabolic disorders; Solid tumours; Viral infections